MedTrace Logo

Gender Differences and Features of the Clinical Course of Primary Headaches

NCT05760625 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2023-03-08

No results posted yet for this study

Summary

The pathophysiological mechanisms that underlie primary headache disorders, such as migraine and cluster headache (CH), are complex and not yet fully clarified. While there is today little doubt that activation of the trigeminovascular system (TGVS) is responsible for the headache pain, the primary mechanisms, probably centrally mediated, leading to its activation and the generation of pain are still largely obscure. The trigeminal system is supposed to play a central role not only in migraine but also in cluster headache pathology. In vitro studies have demonstrated the expression of BDNF in trigeminal ganglion neurons. BDNF release is induced by trigeminal stimulation and nociceptive inputs. BDNF is a member of the neurotrophin family and has been recognized as an important modulator of nociceptive pathways. Interestingly, BDNF is co-expressed with CGRP in trigeminal ganglion neurons. CGRP is one of the key molecules in migraine and cluster headache pathogenesis. BDNF is an important marker of neuronal plasticity. It has also been associated with pain processing. Increased BDNF levels are observed in chronic pain syndromes. In order to understand the role of BDNF associated with other factors such as gender on headache attacks we aimed to determine whether migraine and cluster headache is correlated with brain derived neurotrophic factor (BDNF) level, gender and age.

Conditions

  • Primary Headache Disorder

Interventions

DIAGNOSTIC_TEST

analysis BDNF

We analysed consentration of BDNF in venous blood of patient with primary headache

Sponsors & Collaborators

  • Tashkent Medical Academy

    lead OTHER

Principal Investigators

  • Bahtigul Holmuratova, PhD student · Tashkent Medical Academy

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2022-10-20
Completion
2023-03-21

Countries

  • Uzbekistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05760625 on ClinicalTrials.gov